All articles
Evidence-led research on repurposed compounds and the protocols people actually ask about — cited to primary literature and reviewed for accuracy.
fenbendazole
Fenbendazole Clinical Trials Update 2026: Evidence, Studies & Success Stories
Current state of fenbendazole cancer trials in 2026. What human studies exist, what's in the pipeline, and critical gaps in clinical research.
ASCO Clinical Notice Against Fenbendazole and Ivermectin: What Patients Need to Know (May 2026)
In May 2026, the American Society of Clinical Oncology issued a formal clinical notice recommending against the use of fenbendazole and ivermectin as cancer treatments. We break down what the notice says — and what the emerging observational data shows.
fenbendazole
Panacur C: 77% Hidden Excipients Make It Unsafe for Humans
Complete guide to the viral fenbendazole cancer protocol. Learn exact dosages, supplement combinations, and real patient outcomes from the man who started it all.
Flubendazole + Temozolomide for Glioblastoma: What a 2026 Study Found
A July 2026 study from Charles University found that flubendazole combined with temozolomide reduced glioblastoma cell proliferation and activated apoptosis pathways in three GBM cell lines. Preclinical data only.
fenbendazole
Fenbendazole Success Stories & Case Reports: What Remission Cases Show
Real patient remission cases using fenbendazole protocols. Documented case reports, treatment timelines, and common factors among successful outcomes in Stage IV cancers.
fenbendazole
Fenbendazole and Chemotherapy: Can They Be Combined Safely?
Can fenbendazole be safely combined with chemotherapy? Drug interaction evidence, timing strategies, and potential synergistic or antagonistic effects.
Curcumin Nanoformulations 2025–2026: How Nanotechnology Achieves 178× Bioavailability Improvement
Native curcumin has less than 1% oral bioavailability. A 2025–2026 wave of nanocarrier research (PLGA, liposomes, nanomicelles, stimuli-responsive particles) has achieved up to 178× improvement in plasma AUC. Two nanoformulations — Sinacurcumin and Lipocur — are now in Phase I/II cancer trials.
Ivermectin Outperforms 4 of 5 Chemo Drugs in 2026 Colon Cancer Lab Study
A June 2026 study from UC San Diego found ivermectin combined with recombinant methioninase outperformed four of five first-line chemotherapy drugs against colon cancer cells in vitro, with a chemosensitivity index of 6.7.
fenbendazole
Fenbendazole for Lung Cancer: Comprehensive Research Review 2026
Fenbendazole protocols specifically for lung cancer treatment. Dosing strategies, combination therapies, patient case studies, and mechanisms targeting non-small cell and small cell lung cancers.
Antiparasitic Drugs in Oncology: 2026 Comprehensive Review (7 Drugs, Multiple Cancers)
A 2026 review from Hamad Medical Corporation and Qatar University synthesizes the anticancer evidence for seven antiparasitic drugs — ivermectin, mebendazole, niclosamide, albendazole, artesunate, flubendazole, and pyrvinium pamoate — across multiple cancer types.
Methylene Blue 2025–2026: Neuroprotection, Alzheimer's Disease Trials, Senolytic Activity, and Depression Research
2025–2026 research confirms methylene blue as a mitochondrial electron shuttle that bypasses Complex I dysfunction, reduces ROS by 55–65%, inhibits tau aggregation, reduces senescent cells by ~28%, and shows early signal in treatment-resistant depression. Phase 3 Alzheimer's results remain mixed.
Ivermectin + Mebendazole Show 84.4% Clinical Benefit in 197-Patient Observational Study (Anticancer Research, 2026)
A prospective observational study of 197 cancer patients published in Anticancer Research (2026) found an 84.4% clinical benefit ratio with a compounded ivermectin + mebendazole regimen. Here is a detailed breakdown of the findings.
Nothing here yet.